Use of Novel Hormonal Agents and Systemic Therapy in Advanced Prostate Cancer- Philadelphia (2018)

Philadelphia, PA US
November 10, 2018

Complimentary CME Course! 


(See Official Rules and Regulations Below)

Two Dates, Two Convenient Locations

November  10, 2018  I Philadelphia, PA  Register Now!

Earlier Option held on October 20, 2018 I  Chicago, IL


This page is for registration to the Philadelphia course:

Urologists continue to indicate one of the greatest educational needs in integrating systemic agents into the management of advanced prostate cancer. With numerous new treatments now available to urologists to manage advanced disease, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy.  Urologists play a central role in the management of advanced, metastatic and castrate resistant prostate cancer and as their role continues to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.  

This course will provide essential information on the role of systemic therapy in the treatment of advanced prostate cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by management of castrate sensitive prostate cancer with  systemic agents, sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between agents.  Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.


Advanced Prostate Cancer Course Attendance AUA2019 Drawing

Official Rules

As an incentive to attend the “Use of Novel Hormonal Agents and Systemic Therapies in Advanced Prostate Cancer” course, individual members and non-members who attend the FREE course on November 10, 2018 at The Westin Philadelphia Hotel, will be offered the opportunity to enter a drawing for one FREE AUA2019 Registration (valued at $25 – $2,258 depending on winner’s AUA membership status; registration must be submitted before “early fee” registration deadline) 


This drawing is open only to those who attend the one-day course and who are 21 or older as of the date of entry. Employees of the American Urological Association, their respective affiliates, subsidiaries, suppliers, contractors, and their immediate family members or those living in the same household of each are not eligible to participate. The drawing is subject to all applicable federal, state and local laws and regulations. No purchase is necessary. Void where prohibited. Drawing period: Entries will be accepted starting on or about November 10, 2018 and ending at 5:00 p.m. EST on November 10, 2018.

How to Enter

  • Attend the November 10, 2018 “Use of Novel Hormonal Agents and Systemic Therapies in Advanced Prostate Cancer” course at The Westin Philadelphia Hotel. Winner will selected and announced at 5:00pm. Must be present to win.


The odds of winning depend on the number of entries received. Winner selection and notification: A winner will be selected by random drawing conducted on November 10, 2018 and announced at 5:00pm during the above-mentioned course. The winner must be present to win. If the selected winner is not present when his or her name is called, another entry will be drawn until a winner is identified from among the attendees present.

By entering this contest, you agree to be bound by these rules. You also agree that AUA, its affiliates, or anyone acting on their behalf will have the right, where permitted by law, to print, publish, broadcast, distribute, and use, worldwide and in any media, the winner's name, picture, likeness, voice, statements about the drawing, the course, and/or the AUA, and biographical information as news, publicity, or information, for any purposes and without further consultation or compensation. The sponsor of the drawing is the American Urological Association Education and Research, Inc., 1000 Corporate Boulevard, Linthicum, MD 21090.


Target Audience

  • Urologists
  • Medical Oncologists
  • Radiation Oncologists
  • Advanced Practice Providers
  • Nursing Staff

Learning Objectives

At the conclusion of this activity, participants will be able to: 

  1. Apply the AUA CRPC Guidelines for optimization of the AUA algorithm for patient clinical benefit.
  2. Implement systemic treatment strategies for men with biochemical relapse but non metastatic castration resistant prostate cancer.
  3. Analyze the role of systemic agents in androgen sensitive metastatic prostate cancer.
  4. Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC.
  5. Oversee comorbid conditions and describe their management in the context of CRPC treatment.
  6. Discuss the potential roles of biomarkers in the use of systemic therapy for prostate cancer.
  7. Manage both the acute and chronic pain that is inherent in the care of CRPC patients.
  8. Communicate the pertinent end-of-life issues that surround CRPC patients and their families.


This educational series is supported by independent educational grants from:

Astellas and Pfizer Inc.

Genomic Health

Sanofi Genzyme

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
11/10/2018 - 7:00am EST
Event ends: 
11/10/2018 - 5:30pm EST

7:00 – 8:00 am                       Registration & Continental Breakfast

8:00 – 8:10 am                       Welcome & Introduction                             

8:10 – 8:25 am                       Pre-Test                                


Session I: Guidelines and Treatment Strategies

8:25 – 9:10 am                       Overview of AUA CRPC Guidelines

                                               Daniel W. Lin, MD

9:10 – 9:55 am                       Treatment Sequencing and Combinatorial Strategies in CRPC

                                               Richard J. Lee, MD, PhD                                        

9:55 – 10:00 am                     Session 1 Post-Test                                   

10:00 – 10:15 am                   Break


Session II: Side Effect Management and Toxicities of Therapy

10:15 – 11:00 am                  Comorbidities and Side Effect Profiles – Considerations for Various CRPC                                                                                          Therapeutic Strategies

                                               Atish Choudhury, MD

 11:00 – 11:45 am                  Management of M0 CRPC and Future Directions in Systemic Therapy

              Atish Choudhury, MD       

11:45 am – 12:30 pm             Management of Castrate Sensitive Metastatic Disease and Bone Health

                                               Richard J. Lee, MD, PhD    

12:30 –12:35 pm                    Session II Post-Test

12:35 – 1:45 pm                     Non-CME Lunch Symposium supported by Astellas Pharma US, Inc.


Session III: Enhancing Care through Patient Selection and Clinic Optimization


1:45 – 2:15 pm                       Practical Guide to an Advanced Prostate Cancer Clinic

               Lawrence I. Karsh, MD, FACS

 2:15 – 2:45 pm                       Biomarkers for Advanced Prostate Cancer: Ready for Prime Time?

                                                Daniel W. Lin, MD

2:45 – 2:50 pm                       Session III Post-Test

 Session IV: Quality and End-of Life Issues in CRPC

2:50 – 3:20pm                       Acute and Chronic Pain Management in CRPC

                                               Russell Szmulewitz, MD                                

3:20 – 3:50 pm                       End-of-life Issues in CRPC Patients and Their Families

                                              Russell Szmulewitz, MD

3:50 – 3:55 pm                       Session IV Post-Test                         

3:55 – 4:10 pm                       Break

Session V: Revisiting the Index Patients with a New Perspective

4:10 – 4:50 pm                 Case Study 1 – Metastatic CRPC

Round Table Case Discussions

Questions and Review of Cases


                                            Case Study 2 – M0 CRPC

Round Table Case Discussions

Questions and Review of Cases


4:50 – 5:30 pm                 Case Study 3 – M1 Asymptomatic CRPC/Pre-docetaxel

Round Table Case Discussions

Questions and Review of Cases


                                           Case Study 4 – M1 Symptomatic Post-docetaxel

Round Table Case Discussions

Questions and Review of Cases


5:30 pm                              Course Adjourn

The Westin Philadelphia
99 South 17th Street at Liberty Place
Philadelphia, PA 19103
United States
+1 (215) 563-1600

The AUA recommends that you register for the course BEFORE making travel arrangements. Once the meeting capacity is reached, which may be prior to the early-bird date, the AUA is unable to guarantee a spot in the course.

Hotel Information

To hold a reservation, a major credit card number must be provided.

Room Rate: $219 single/double occupancy. To make your reservation please visit The Westin Philadelphia Reservations  or call (215) 563-1600 and reference the AUA Advanced Prostate Cancer Course to receive the special group rate. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.

Cut-off Date: Friday, October 12, 2018. Guest rooms may not be available at the AUA special rate after this date.

Check-in: 3 p.m.
Check-out: Noon

Car Rental

Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code CDP# 053G0001


Book early! Rooms may not be available as the meeting dates approach.
Conference rooms can be cold, please bring a sweater or jacket to the conference.


Call 1-800-908-9414 or e-mail

Course Director(s)

Daniel Lin, MD

has no relevant financial relationships to disclose at this time.

Atish Choudhury, MD

has no relevant financial relationships to disclose at this time.

Lawrence Karsh, MD, FACS

has no relevant financial relationships to disclose at this time.

Richard Lee, MD

has no relevant financial relationships to disclose at this time.

Russell Szmulewitz,

has no relevant financial relationships to disclose at this time.


Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation
Please login or register to take this course.

Registration for this course is complimentary; however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting registration at 1-410-689-3930. 

AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before September 28, 2018. If AUA Education & Research cancels this course, notification will be sent by October 5, 2018.